← Back to Search

Angiotensin Receptor-Neprilysin Inhibitor

LCZ696 for Hypertrophic Cardiomyopathy

Phase 2

Waitlist Available

Research Sponsored by Novartis Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 50 weeks

Awards & highlights

Study Summary

This trial will test if a drug, LCZ696, is safe and effective in treating people with non-obstructive hypertrophic cardiomyopathy over 50 weeks.

Eligible Conditions

Hypertrophic Cardiomyopathy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 50 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 50 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 50 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline in peak VO2 as measured by cardiopulmonary exercise test (CPET)

Side effects data

From 2018 Phase 4 trial • 1002 Patients • NCT02661217

14%

Hypotension

12%

Hyperkalaemia

Cardiac failure

Diarrhoea

Dizziness

Oedema peripheral

Renal impairment

Urinary tract infection

Cardiac failure acute

Pneumonia

Dyspnoea

Respiratory tract infection

Chronic obstructive pulmonary disease

Syncope

Acute myocardial infarction

Atrial fibrillation

Non-cardiac chest pain

Gastroenteritis

Acute kidney injury

Renal failure

Pulmonary oedema

Cardiogenic shock

Bronchitis

Erysipelas

Cardiac failure congestive

100%

80%

60%

40%

20%

Study treatment Arm

Post-discharge

Pre-discharge

All Patients

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: LCZ696 at doses of 50mg, 100mg and 200mg b.i.dExperimental Treatment1 Intervention

randomized in a 1:1 ratio: LCZ696 to placebo

Group II: Placebo to LCZ696Placebo Group1 Intervention

randomized in a 1:1 ratio: LCZ696 to placebo

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

LCZ696

2016

Completed Phase 4

~14630

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor

2,855 Previous Clinical Trials

4,197,308 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there other similar medical studies involving LCZ696?

"LCZ696 is being trialed in 39 separate studies at the moment, 8 of which are Phase 3 trials. The majority of these Montreal-based studies have 812 locations."

Answered by AI

Is this study currently looking for participants?

"Yes, this clinical trial is still recruiting patients according to information found on clinicaltrials.gov. This specific trial was posted on 1/8/2020 and was last edited more recently on 11/15/2022."

Answered by AI

What indications does LCZ696 commonly treat?

"LCZ696 is often employed to ameliorate left ventricular dysfunction. Additionally, this medication can be used for essential hypertension and prophylaxis of cardiovascular event when monotherapy has failed to adequately control the condition."

Answered by AI

Could you tell me if LCZ696 is an FDA-endorsed medication?

"LCZ696 has not been proven effective yet in clinical trials, however, there is some evidence that it is safe. This earns LCZ696 a safety score of 2."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

2020. "Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04164732.